Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.
about
Early detection of diabetic kidney disease: Present limitations and future perspectivesBiomarkers of Renal Disease and Progression in Patients with DiabetesClinical therapeutic strategies for early stage of diabetic kidney disease.Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria.Turmeric: Reemerging of a neglected Asian traditional remedy.A story of microalbuminuria and diabetic nephropathyEculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy.Association of race/ethnicity, inflammation, and albuminuria in patients with diabetes and early chronic kidney diseaseInflammation in diabetic kidney diseaseProteomic discovery of diabetic nephropathy biomarkers.Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart StudyOral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.TNF-α and microalbuminuria in patients with type 2 diabetes mellitus.Pirfenidone for diabetic nephropathy.Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes.Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy.Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes.Circulating Tumor Necrosis Factor α Receptors Predict the Outcomes of Human IgA Nephropathy: A Prospective Cohort Study.Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes.Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetesGene Co-Expression Network Analysis for Identifying Modules and Functionally Enriched Pathways in Type 1 Diabetes.Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes.Soluble Tumor Necrosis Factor Receptor 1 Is Associated with Glomerular Filtration Rate Progression and Incidence of Chronic Kidney Disease in Two Community-Based Cohorts of Elderly Individuals.Diabetic nephropathy: What does the future hold?Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes.Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes.Postexercise phosphocreatine recovery, an index of mitochondrial oxidative phosphorylation, is reduced in diabetic patients with lower extremity complicationsIncreased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes.Systemic and renal lipids in kidney disease development and progression.Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.Early nephropathy in type 1 diabetes: the importance of early renal function decline.Plasma apolipoprotein L1 levels do not correlate with CKD.Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases.Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors.Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.Biomarkers in diabetic nephropathy: Present and future.Body fluid peptide and protein signatures in diabetic kidney diseases.The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.
P2860
Q26741494-32CE14D8-3FB6-4CF6-90C5-8A4B639AD815Q26799505-42445CB0-46E9-428C-84F6-329FB028D5EEQ30363683-B9C2F40B-1128-4007-A841-1811A0EFAE92Q30371076-EF7DD4C2-29FD-4939-AC5C-F52AB1FE8463Q30486649-C87A5DB0-B56F-46F0-8125-09572BF16A40Q30486667-897AFA4C-C50A-420A-9E33-B634B572723BQ33421669-39EBB29A-9FD4-4A3F-91A3-DD6A4676EBFBQ33772238-41156802-360C-41E4-B780-AE05EA37EC81Q33801646-26C97521-0D6A-4F5E-9985-E8689D94BAE2Q34023543-283527B2-9D46-455C-9E68-3641012EBF52Q34330236-8E32F319-0ED1-40EE-A7A1-080B7D1456D4Q34336370-77AE097A-5FF0-496D-AE3A-8A47EF040DC6Q34476839-B3B65A50-97F9-4CF2-BFAB-36DB9F089581Q34629660-36627799-8D0B-4B6C-A92E-AD6DFC908421Q34838338-7FB4BA13-FD5F-48F9-941F-3E0C861A6F0FQ35012444-E0011DF5-2AB8-4739-AAA4-445305012AAFQ35243559-2F2FE0EC-ABCB-4269-9EEC-E8CAD3979139Q35364638-37219A71-3576-4AFF-B9B7-1C571E0845DFQ35630730-1C03F625-3337-4D83-8070-76159979D372Q35692544-41158CEA-A216-49A1-9680-DC9250619999Q35804154-FB1F2527-50D0-4120-98D1-60BA7214ED1BQ35804201-1488C8B1-8AB4-44A1-B062-6708455C4E51Q36039529-BCC59A42-5D46-4120-8B78-6FF7F22B8FAEQ36200281-BE018311-4824-400D-A522-7080E68581E6Q36325841-4A92B26D-F554-4134-B6DF-643A2CC36A12Q36441616-D53A1F4D-3D9A-4D67-BC88-5403D059E253Q36629282-7553182B-45A4-4149-8D0F-6C2A0BD36621Q36723318-F2F013A1-82C6-4594-81B6-BBA73679530EQ36728193-46A0E859-3FCC-4FC2-8812-5C70B8239F3AQ36844894-1DCB8D70-F10F-4915-8568-12A925E591CFQ37148885-F100B244-C070-4FD4-9D2A-0738C11891D3Q37403180-59134C62-BE5C-49C3-83F5-F0F5655C69E8Q37418807-0D5B3015-4221-4F41-A4D9-FD4415244263Q37604753-BE9616E7-83F4-4D6C-8E3F-1A1CB5452AA2Q38042322-9F538B36-4F2F-42D5-AEDA-2063749821D3Q38105277-F7A6F6EF-FE36-4B93-85EC-48BFEF8A91EBQ38255902-92D689A6-7C84-47DC-9399-D6428EA4131BQ38290083-590DCD34-B80B-4F40-8848-E0447E347045Q38553924-D32EA052-3096-4035-84FC-DBE270D39369Q38786133-60427316-2254-420B-9A9C-1264E890454E
P2860
Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum concentrations of marker ...... patients with type 1 diabetes.
@en
Serum concentrations of marker ...... patients with type 1 diabetes.
@nl
type
label
Serum concentrations of marker ...... patients with type 1 diabetes.
@en
Serum concentrations of marker ...... patients with type 1 diabetes.
@nl
prefLabel
Serum concentrations of marker ...... patients with type 1 diabetes.
@en
Serum concentrations of marker ...... patients with type 1 diabetes.
@nl
P2093
P2860
P356
P1476
Serum concentrations of marker ...... patients with type 1 diabetes
@en
P2093
Amanda C Johnson
Andrzej S Krolewski
Bijan Roshan
Elizabeth T Rosolowsky
James H Warram
Monika A Niewczas
William Walker
P2860
P356
10.2215/CJN.03010608
P577
2008-12-10T00:00:00Z